Search

everythinglearnresearchcommunity

for

Search:↓

The PTH-CBD injection improved hair regrowth better than the daily ruxolitinib pill in mice.

Tocilizumab treatment was associated with significant hair regrowth in one patient and temporary hair loss followed by regrowth in another.

Clofazimine effectively treated ashy dermatosis in a patient.

Leflunomide and anthralin may effectively treat severe alopecia areata.

Azathioprine can help with relapses and disability in NMOSD but has more side effects and needs more research.

The combination of the excimer lamp and liquor carbonis detergens is more effective for scalp psoriasis than the lamp alone.

Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.

Targeting specific biomarkers and immune signals is more effective and safer for treating inflammatory skin diseases.

Blocking EGFR can cause skin inflammation by disrupting IL-1 signaling.

JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.

The new cocrystal KET-PABA is a more effective and safe anti-inflammatory treatment for skin conditions in mice.

New medications could improve treatment for severe alopecia areata in Australia.

Upadacitinib effectively treated severe hair loss in a child.

Both treatments improved alopecia areata, but methotrexate caused more skin darkening, while triamcinolone caused skin lightening and thinning.

Renal transplant patients on tacrolimus and sirolimus may develop acne keloidalis nuchae.

Tofacitinib might be used to treat hair loss.

Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.

Both treatments for localized alopecia areata are equally effective.

Tofacitinib helped an 8-year-old child recover from a type of hair loss that is hard to treat.

Dupilumab can cause rare side effects like a rash on the face and neck.

Some drugs used to treat inflammation may cause hair loss.

IL-17C is important in inflammatory skin diseases and could be a target for treatment.

Tocilizumab therapy may cause skin and hair conditions like halo naevi, vitiligo, and alopecia areata.

Dupilumab may help treat alopecia areata in children with atopic dermatitis, but it can also cause new hair loss.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

Ruxolitinib helps regrow hair in alopecia areata by blocking inflammation, reducing stress, and controlling cell death.

Adding dupilumab led to almost complete hair regrowth in a patient with alopecia areata who only partially responded to baricitinib.